2026-02-24
Senolytics and Cellular Senescence: Mechanisms, Mayo Clinic Evidence, and Clinical Status
Senolytics are drugs and compounds that selectively clear senescent cells, which accumulate with age and drive chronic inflammation. This review covers the mechanisms, the Mayo Clinic dasatinib+quercetin trials, fisetin evidence, and the current clinical status.
2026-02-24
Vision and Age-Related Macular Degeneration: Lutein, Zeaxanthin, and AREDS2 Evidence
The AREDS2 trial established lutein and zeaxanthin as replacements for beta-carotene in the AMD supplement formula, reducing progression risk by 25% in high-risk eyes. Dietary intake from dark leafy greens provides equivalent carotenoids. This article explains what the evidence supports and what it does not.
2026-02-19
Polyphenol Protocols in Cognition Clinics: Clinical Context and Evidence Limits
Resveratrol, quercetin, and fisetin are used in some cognition-focused protocols, but human evidence is mixed and best interpreted as adjunctive support rather than primary therapy.
2026-02-18
Partial Epigenetic Reprogramming for Vision Loss: Life Biosciences ER-100 Trial
Life Biosciences received FDA clearance to begin the first human trial of partial epigenetic reprogramming using OSK Yamanaka factors delivered via AAV for glaucoma and NAION. Trial is in early stages; no human efficacy data exists yet.
2026-02-18
Gene Therapy for Telomere Biology Disorders: EXG-34217 Trial Results at Cincinnati Children's
EXG-34217, a gene therapy delivering functional TERT, showed telomere elongation and hematopoietic recovery in two patients with dyskeratosis congenita — a rare inherited disease, not general aging. Results published in NEJM Evidence.